Advertisement
Screener

VYOME HOLDINGS, INC. (HIND) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

VYOME HOLDINGS, INC. Financing Cash Flow

VYOME HOLDINGS, INC. (HIND) reported Financing Cash Flow of $5.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12

  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$3.00K, a 100.48% decline year-over-year.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.29M, a 3205.54% increase year-over-year.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $764.02K, a 1328.98% increase year-over-year.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $7.10M, a 2495.45% increase year-over-year.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $8.65M, a 1140.05% increase from fiscal 2024.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $697.95K, a 96.03% decline from fiscal 2023.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $17.57M, a 461.47% increase from fiscal 2022.
  • VYOME HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $3.13M, a 90.60% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30-$3.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$5.29M
10-Q · filed 2026-08-12
$6.05M
derived: sum of 3 quarters · filed 2026-08-12
$13.15M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$5.29M
10-Q · filed 2026-05-12
$6.05M
derived: sum of 2 quarters · filed 2026-05-12
$13.15M
derived: sum of 3 quarters · filed 2026-05-12
$13.78M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$764.02K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$7.86M
derived: sum of 2 quarters · filed 2026-03-18
$8.49M
derived: sum of 3 quarters · filed 2026-08-12
$8.65M
10-K · filed 2026-03-18
2025-09-30$7.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$7.73M
derived: sum of 2 quarters · filed 2026-08-12
$7.89M
10-Q · filed 2025-11-14
$7.94M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$631.25K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$791.25K
10-Q · filed 2026-08-12
$10.05M
10-Q · filed 2025-08-14
$844.72K
derived: sum of 3 quarters · filed 2026-08-12
$1.12M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$160.00K
10-Q · filed 2026-05-12
$3.95M
10-Q · filed 2025-05-20
$213.47K
derived: sum of 2 quarters · filed 2026-05-12
$487.01K
derived: sum of 3 quarters · filed 2026-05-12
2024-12-31$53.47K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$327.01K
derived: sum of 2 quarters · filed 2026-03-18
$697.95K
10-K · filed 2026-03-18
$677.00K
10-K · filed 2025-04-04
2024-09-30$273.54K
derived: 10-Q 9 month − 8-K 6 month · filed 2025-11-14
$644.49K
10-Q · filed 2025-11-14
$24.00K
10-Q · filed 2024-11-14
2024-06-30$370.94K
8-K · filed 2025-09-02
$24.00K
10-Q · filed 2024-08-14
2023-12-31$5.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-04
$5.12M
derived: sum of 2 quarters · filed 2025-04-04
$7.37M
derived: sum of 3 quarters · filed 2025-04-04
$17.57M
10-K · filed 2025-04-04
2023-09-30-$338.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$1.91M
derived: sum of 2 quarters · filed 2024-11-14
$12.11M
10-Q · filed 2024-11-14
$12.75M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$2.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$12.45M
10-Q · filed 2024-08-14
$13.09M
derived: sum of 3 quarters · filed 2024-08-14
$13.09M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$10.20M
10-Q · filed 2024-05-15
$10.84M
derived: sum of 2 quarters · filed 2024-05-15
$10.84M
derived: sum of 3 quarters · filed 2024-05-15
2022-12-31$638.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$641.00K
derived: sum of 2 quarters · filed 2024-04-01
$3.13M
10-K · filed 2024-04-01
2022-09-30$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$2.49M
10-Q · filed 2023-11-09
2022-06-30$2.49M
10-Q · filed 2023-08-07
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17
-$3.03M
derived: sum of 2 quarters · filed 2023-04-17
$32.30M
derived: sum of 3 quarters · filed 2023-04-17
$33.30M
10-K · filed 2023-04-17
2021-09-30-$3.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$32.30M
derived: sum of 2 quarters · filed 2022-11-14
$33.30M
10-Q · filed 2022-11-14
$38.37M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$35.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-19
$36.33M
10-Q · filed 2022-08-19
$41.40M
derived: sum of 3 quarters · filed 2022-08-19
$42.90M
derived: sum of 4 quarters · filed 2022-08-19
2021-03-31$1.00M
10-Q · filed 2022-05-23
$9.51M
10-Q · filed 2021-05-12
$6.07M
derived: sum of 2 quarters · filed 2022-05-23
$7.57M
derived: sum of 3 quarters · filed 2022-05-23
$12.07M
derived: sum of 4 quarters · filed 2022-05-23
2020-12-31$5.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08
$6.57M
derived: sum of 2 quarters · filed 2022-04-08
$11.07M
derived: sum of 3 quarters · filed 2022-04-08
$11.07M
10-K · filed 2022-04-08
$430.00K
10-K · filed 2021-03-12
2020-09-30$1.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$6.01M
derived: sum of 2 quarters · filed 2021-11-12
$6.01M
10-Q · filed 2021-11-12
$430.00K
10-Q · filed 2020-11-06
$5.71M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$4.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
$4.51M
10-Q · filed 2021-08-16
$430.00K
10-Q · filed 2020-07-30
$4.21M
derived: sum of 3 quarters · filed 2021-08-16
$14.09M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$0.00
10-Q · filed 2021-05-12
-$296.00K
derived: sum of 2 quarters · filed 2021-05-12
$9.58M
derived: sum of 3 quarters · filed 2021-05-12
$2.77M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31-$296.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
$9.58M
derived: sum of 2 quarters · filed 2021-03-12
$2.77M
derived: sum of 3 quarters · filed 2021-03-12
$13.38M
10-K · filed 2021-03-12
2019-09-30$9.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
$3.07M
derived: sum of 2 quarters · filed 2020-11-06
$13.67M
10-Q · filed 2020-11-06
$13.54M
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30-$6.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$3.79M
10-Q · filed 2020-07-30
$3.66M
derived: sum of 3 quarters · filed 2020-07-30
$13.61M
derived: sum of 4 quarters · filed 2020-07-30
2019-03-31$10.61M
10-Q · filed 2020-06-19
$10.47M
derived: sum of 2 quarters · filed 2020-06-19
$20.42M
derived: sum of 3 quarters · filed 2020-06-19
$20.57M
derived: sum of 4 quarters · filed 2020-06-19
2018-12-31-$135.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$9.81M
derived: sum of 2 quarters · filed 2020-02-27
$9.97M
derived: sum of 3 quarters · filed 2020-02-27
$9.99M
10-K · filed 2020-02-27
2018-09-30$9.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$10.10M
derived: sum of 2 quarters · filed 2019-11-08
$10.13M
10-Q · filed 2019-11-08
$10.49M
derived: sum of 4 quarters · filed 2019-11-08
2018-06-30$151.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24
$179.00K
10-Q · filed 2019-07-24
$536.00K
derived: sum of 3 quarters · filed 2019-07-24
$545.00K
derived: sum of 4 quarters · filed 2019-07-24
2018-03-31$28.00K
10-Q · filed 2019-05-10
$385.00K
derived: sum of 2 quarters · filed 2019-05-10
$394.00K
derived: sum of 3 quarters · filed 2019-05-10
$641.00K
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$357.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
$366.00K
derived: sum of 2 quarters · filed 2019-02-22
$613.00K
derived: sum of 3 quarters · filed 2019-02-22
$613.00K
10-K · filed 2019-02-22
2017-09-30$9.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02
$256.00K
derived: sum of 2 quarters · filed 2018-11-02
$256.00K
10-Q · filed 2018-11-02
$67.47M
derived: sum of 4 quarters · filed 2018-11-02
2017-06-30$247.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
$247.00K
10-Q · filed 2018-08-02
$67.47M
derived: sum of 3 quarters · filed 2018-08-02
$68.50M
derived: sum of 4 quarters · filed 2018-08-02
2017-03-31$0.00
10-Q · filed 2018-05-10
$67.22M
derived: sum of 2 quarters · filed 2018-05-10
$68.26M
derived: sum of 3 quarters · filed 2018-05-10
$82.78M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$67.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05
$68.26M
derived: sum of 2 quarters · filed 2018-03-05
$82.78M
derived: sum of 3 quarters · filed 2018-03-05
$82.79M
10-K · filed 2018-03-05
2016-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03
$15.56M
derived: sum of 2 quarters · filed 2017-11-03
$15.57M
10-Q · filed 2017-11-03
2016-06-30$14.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$14.53M
10-Q · filed 2017-08-02
2016-03-31$2.00K
10-Q · filed 2017-05-10
2015-12-31$5.06M
10-K · filed 2018-03-05
2014-12-31$22.19M
10-K · filed 2017-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36